<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Anesthesiol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Anesthesiol</journal-id><journal-title-group><journal-title>BMC Anesthesiology</journal-title></journal-title-group><issn pub-type="epub">1471-2253</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28222674</article-id><article-id pub-id-type="pmc">5320746</article-id><article-id pub-id-type="publisher-id">320</article-id><article-id pub-id-type="doi">10.1186/s12871-017-0320-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Administration of HES in elderly patients undergoing hip arthroplasty under spinal anesthesia is not associated with an increase in renal injury</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuanyuan</given-names></name><address><email>doctorkelly@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Yonghao</given-names></name><address><phone>+8613920590099</phone><email>zyymzkzyy@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Junya</given-names></name><address><email>jiajunya@126.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Wenli</given-names></name><address><email>yzxyuwenli@163.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Rubin</given-names></name><address><email>daruxu@163.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Geng</surname><given-names>Licheng</given-names></name><address><email>genglicheng2003@yahoo.com.cn</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Ying</given-names></name><address><email>weiying927@163.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 9434</institution-id><institution-id institution-id-type="GRID">grid.412645.0</institution-id><institution>Department of Anaesthesiology, </institution><institution>Tianjin Medical University General Hospital, </institution></institution-wrap>Anshan Road 154#, Heping District, Tianjin, CN 300052 People&#x02019;s Republic of China </aff><aff id="Aff2"><label>2</label>Tianjin Research Institute of Anaesthesiology, Anshan Road 154#, Heping District, Tianjin, CN 300052 People&#x02019;s Republic of China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 9434</institution-id><institution-id institution-id-type="GRID">grid.412645.0</institution-id><institution>Department of Nephron, </institution><institution>Tianjin Medical University General Hospital, </institution></institution-wrap>Anshan Road 154#, Heping District, Tianjin, CN 300052 People&#x02019;s Republic of China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0605 6814</institution-id><institution-id institution-id-type="GRID">grid.417024.4</institution-id><institution>Department of Anaesthesiology, </institution><institution>Tianjin First Central Hospital, </institution></institution-wrap>Fukang Road 24#, Nankai District, Tianjin, CN 300192 People&#x02019;s Republic of China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1799 2675</institution-id><institution-id institution-id-type="GRID">grid.417031.0</institution-id><institution>Department of Anaesthesiology, </institution><institution>Tianjin People&#x02019;s Hospital Tianjin Union Medical Center, </institution></institution-wrap>Jieyuan Road 190#, Hongqiao District, Tianjin, CN 300121 People&#x02019;s Republic of China </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>17</volume><elocation-id>29</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Hydroxyethyl starch (HES) is applied to achieve volume expansion during surgery; however, nephrotoxicity may be induced in patients with sepsis. Simultaneously, neutrophil gelatinase-associated lipocalin (NGAL) and IL-18 have been illustrated as pivotal indicators to diagnose the acute kidney injury (AKI) early. This multi-center, randomized, double-blinded, placebo-controlled study aimed to investigate whether 6% HES 130/0.4 administration caused postoperative AKI, which can be revealed by urinary and plasma NGAL and IL-18 estimations in elderly patients with normal renal function undergoing hip arthroplasty under spinal anesthesia.</p></sec><sec><title>Methods</title><p>120 ASA I&#x02013;III, patients aged &#x0003e;65 y undergoing hip arthroplasty under spinal anesthesia randomly received 6% HES 130/0.4 or sodium lactate Ringer&#x02019;s solution 7.5&#x000a0;mL/kg during the first hour of surgery. 118 patients completed the study. Blood pressure, NGAL concentrations, IL18, &#x003b2;<sub>2</sub> micro-albumin and albumin in urine and creatinine, NGAL and IL-18 in plasma were repeatedly measured before, during, and after surgery.</p></sec><sec><title>Results</title><p>The groups were balanced in mean arterial pressure, urine and plasma NGAL, plasma IL-18 and creatinine, urine &#x003b2;<sub>2</sub> microalbumin and albumin (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). Urine IL-18 was dramatically elevated in both groups after surgery (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), but did not vary significantly between the groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05).</p></sec><sec><title>Conclusion</title><p>Elderly patients undergoing surgery under spinal anesthesia are a high-risk population in AKI. These patients with normal renal function receiving a spinal anesthesia for a short duration surgery would not develop AKI when 500&#x000a0;mL (small volume) HES is infused.</p></sec><sec><title>Trial registration</title><p>Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=NCT02361736&#x00026;Search=Search">NCT02361736</ext-link>. Registration date was 2 February 2015.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Acute kidney injury</kwd><kwd>Elderly patients</kwd><kwd>Hydroxyethyl starch</kwd><kwd>IL-18</kwd><kwd>NGAL</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81471842</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Yonghao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Hydroxyethyl starch (HES) is infused to sustain circulation in patients undergoing surgery and suffering from trauma and critical disease [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. However, these patients may be subsequently complicated by acute kidney injury (AKI), and HES might effectuate adverse events in renal function. The principal detection of AKI is a rapid increase in plasma creatinine (p-crea) or a sudden drop in urine output [<xref ref-type="bibr" rid="CR4">4</xref>]. Sex, age, medication, nutrition, and muscle mass exerts a crucial effect on p-crea [<xref ref-type="bibr" rid="CR5">5</xref>]. Simultaneously, the level of p-crea is upregulated at 24&#x02013;48&#x000a0;h after renal damage, and hence, the diagnosis of AKI is delayed when p-crea is the sole biomarker for renal injury. Remarkable progress has been made in recent years with respect to achieving an earlier diagnosis of AKI via the evaluation of biomarkers in urine [<xref ref-type="bibr" rid="CR6">6</xref>]. Neutrophil gelatinase&#x02013;associated lipocalin (NGAL) is a small protein, filtered via the glomeruli and reabsorbed in the proximal tubules, and thus, the low concentrations can be assessed in the blood and urine [<xref ref-type="bibr" rid="CR7">7</xref>]. Approximately 6&#x000a0;h after a renal injury, NGAL experiences an abrupt upsurge attributable to an increasing expression and secretion in the epithelial cells of the thick ascending limb of Henle&#x02019;s loop, the distal tubules, and the collecting ducts [<xref ref-type="bibr" rid="CR7">7</xref>]. On the other hand, NGAL has been demonstrated and substantiated to predict AKI; malignancies and infections can engender a false increase [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Interleukin 18 (IL-18) is an18 kDa cytokine, which is identified as a co-stimulatory factor for the generation of interferon-&#x003b3; (IFN-&#x003b3;) in response to toxic shock syndrome. IL-18 shares functional similarities with IL-12, and is synthesized as a 24&#x000a0;kDa precursor molecule without a signal peptide that must be cleaved to produce an active molecule. IL-18 is principally produced from proximal kidney tubules and is a pro-inflammatory factor that can be detected in the urine of earlier AKI animal models. A remarkable upsurge in IL-18 levels in urine during AKI is confirmed in several clinical studies [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. The specificity and susceptibility of IL-18 used in AKI diagnosis is 90%. As a result, IL-18 can be chosen as an effective biomarker to predict AKI.</p><p>Intravenous treatment with HES leads to its excretion in urine but is also partially absorbed in the tissues [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Several experimental and clinical studies reported that HES molecules were accumulated in the proximal tubule cells with subsequent vacuolization and swelling&#x02014;a condition known as osmotic nephrosis [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Recent studies showed that the renal function was impaired when tetrastarch was delivered in patients with sepsis [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. However, perioperative studies failed to discover the association between AKI occurrence and HES infusion [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>We hypothesized that 6% HES 130/0.4 exerted a nephrotoxic effect in elderly patients, which could be revealed by the assessment and measurements of NGAL and IL-18 levels as a primary outcome [<xref ref-type="bibr" rid="CR24">24</xref>]. The hemodynamics data, plasma creatinine, urine &#x003b2;<sub>2</sub> microalbumin, and albumin were the secondary outcomes and also documented. The pharmacokinetic property of Ringer&#x02019;s lactated solution, different from colloids, cannot contribute to acute kidney injury in clinics [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]; therefore, we selected the infusion of Ringer&#x02019;s lactate as the control.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p>The American Society of Anesthesiologists (ASA) physical status I-III of patients aged &#x0003e;65y scheduled for hip arthroplasty under spinal anesthesia were contacted, informed about the study, and enrolled after written consent was acquired. Exclusion Criteria: any allergy and contraindication to 6% HES 130/0.4; infections and malignancies; sepsis; history of heart failure or NYHA&#x02009;&#x0003e;&#x02009;III; pre-existing renal failure or Cr &#x0003e;108&#x000a0;&#x003bc;mol/L, BUN &#x0003e;8.3&#x000a0;mmol/L; undergoing dialysis treatment; intracranial hemorrhages; long-lasting intake of any non-steroidal anti-inflammatory agent; inability to understand the study information sheet and provide a written consent for participation in the study.</p></sec><sec id="Sec4"><title>Intervention</title><p>Patients were randomly divided into one of the two groups: (1) patients in group LR received intraoperative placebo lactate Ringer&#x02019;s at a dose of 7.5&#x000a0;mL/kg; (2) patients in group HES received 6% HES 130/0.4 at a dose of 7.5&#x000a0;mL/kg during the first hour of surgery, followed by administration of 5&#x000a0;mL/kg lactate Ringer&#x02019;s until the end of the surgery.</p></sec><sec id="Sec5"><title>Randomization</title><p>The patients were randomly assigned to treatment regimens via a randomization list provided by the Department of Anesthesiology, Tianjin Medical University General Hospital, according to the relevant Standard Operating Procedure (computer-generated random number system). The allocation sequence was concealed until after consent was obtained.</p></sec><sec id="Sec6"><title>Blinding</title><p>The patients and a treating anesthesiologist involved in the perioperative patient management were incognizant of the group assignment. Primary and secondary outcomes were measured and recorded by another anesthesiologist responsible for data collection, but not involved in the direct treatment of the participating patients and thus, blinded to randomization.</p></sec><sec id="Sec7"><title>Procedures and outcomes</title><p>All the patients were fasting 12&#x000a0;h before surgery. Upon arrival in the operation theater, the patients were monitored by electrocardiography, pulse oximeter, and noninvasive blood pressure. In addition, a peripheral intravenous line in the left arm and urinary catheter were also attached before anesthesia induction. Subsequent to the collection of the first blood and urine samples, the fluid was infused and mean arterial blood pressure (MAP), heart rate (HR), and arterial saturation were monitored. Then, Cefazolin sodium was injected at prophylactic doses of 2&#x000a0;g in every patient. Spinal anesthesia was administered to the patient in the lateral decubitus position, side of surgery downwards, lumbar puncture preferably midline at L<sub>3</sub>-L<sub>4</sub> with a pencil point 25-gauge needle. 10&#x000a0;mg Ropivacaine was injected into the subdural space. After 15&#x000a0;min, the patient was maneuvered to a supine. If bradycardia (HR &#x0003c;45 beats/min) and continuous hypotension (MAP &#x0003c;60&#x000a0;mmHg) persisted, additional fluid infusion, atropine (0.5&#x000a0;mg) and phenylephrine (0.1&#x000a0;mg) were also administered. Supplemental oxygen was provided via a nasal cannula. Hemodynamics data was evaluated and recorded at baseline (T<sub>0</sub>), before skin incision (T<sub>1</sub>), at skin incision (T<sub>2</sub>), after skin incision (T<sub>3</sub>), and surgery completion (T<sub>4</sub>). A mean value at every time point was calculated for statistical analysis.</p><p>The blood and urine samples were obtained at five time-points: before anesthesia (D<sub>0</sub>), during surgery (D<sub>1</sub>), the first day after surgery (D<sub>2</sub>), the third day after surgery (D<sub>3</sub>), and the fifth day after surgery (D<sub>4</sub>). The postoperative urine and blood samples were collected at 8:00 a.m when patients were fasted, on D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub>.</p><p>All the urine and blood samples were centrifuged for 10&#x000a0;min at 3500&#x000a0;r/min at 4&#x000a0;&#x000b0;C. Consequently, the samples were maintained at -80&#x000a0;&#x000b0;C until assayed and re-centrifuged before usage in order to minimize any impurities. Every analysis was conducted consecutively by the same laboratory technician to minimize variability in the results.</p><p>Creatinine was measured by the sarcosine oxidase method using the commercial kit from Nanjing Jiancheng Bioengineering Institute. The concentration of IL-18 in plasma and urine were assessed by Human IL-18 ELISA Kit (Nanjing Jiancheng Bioengineering Institute). The concentration of NGAL in plasma and urine were measured by Human NGAL ELISA Kit (Nanjing Jiancheng Bioengineering Institute). The urine &#x003b2;<sub>2</sub> microalbumin and trace albumin were measured by Human &#x003b2;<sub>2</sub>-MG ELISA kit and Human mALB Elisa kit (Nanjing Jiancheng Bioengineering Institute).</p><p>The estimated glomerular filtration rate (eGFR) was documented by plasma creatinine through CKD-EPI2009. The 24&#x000a0;h urinary protein quantity was altered by the ratio of urine trace albumin and urine creatinine (ACR). The reference interval of ACR is 0&#x02013;2.5 for males and 0&#x02013;3.0 for females.</p></sec></sec><sec id="Sec8"><title>Results</title><p>A cohort of 120 patients was included. One patient was excluded before intervention due to urine tube failure. One patient was excluded due to hemolysis after centrifugation. Thus, 59 patients were allocated to the LR group and 59 to the HES group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of study</p></caption><graphic xlink:href="12871_2017_320_Fig1_HTML" id="MO1"/></fig>
</p><p>Age, sex, ASA, operation time, and the amount of liquid administered to patients, blood loss, patients needing phenylephrine, phenylephrine dose per patient and length of stay in both the groups were similar (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The two groups were comparable regarding comorbidities (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). During the span of the entire study, any adverse reactions were not reported.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics and intraoperative data</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Male/Female</th><th>Age (yr)</th><th>ASA status (I/II/III)</th><th>Operation time (min)</th><th>Fluid infusion (ml)</th><th>Blood loss (ml)</th><th>Patients needing phenylephrine, no.(%)</th><th>Phenylephrine dose per patient(mg)</th><th>Length of stay (d)</th></tr></thead><tbody><tr><td>HES</td><td>31/28</td><td char="&#x000b1;" align="char">75.9&#x02009;&#x000b1;&#x02009;7.5</td><td>39/15/5</td><td char="&#x000b1;" align="char">56&#x02009;&#x000b1;&#x02009;4</td><td char="&#x000b1;" align="char">490&#x02009;&#x000b1;&#x02009;30</td><td char="&#x000b1;" align="char">100&#x02009;&#x000b1;&#x02009;40</td><td>2(3.4)</td><td char="&#x000b1;" align="char">0.1&#x02009;&#x000b1;&#x02009;0.04</td><td char="&#x000b1;" align="char">10.5&#x02009;&#x000b1;&#x02009;1.7</td></tr><tr><td>LR</td><td>29/30</td><td char="&#x000b1;" align="char">76.4&#x02009;&#x000b1;&#x02009;8.1</td><td>37/14/8</td><td char="&#x000b1;" align="char">58&#x02009;&#x000b1;&#x02009;5</td><td char="&#x000b1;" align="char">510&#x02009;&#x000b1;&#x02009;20</td><td char="&#x000b1;" align="char">120&#x02009;&#x000b1;&#x02009;50</td><td>5(8.5)</td><td char="&#x000b1;" align="char">0.15&#x02009;&#x000b1;&#x02009;0.06</td><td char="&#x000b1;" align="char">11.2&#x02009;&#x000b1;&#x02009;1.1</td></tr></tbody></table><table-wrap-foot><p>Values are no. (%) or means(SD)</p><p>Patients in group LR received intraoperative placebo Lactate Ringers&#x02019; at a dose of 7.5&#x000a0;ml/kg; Patients in group HES received 6% HES 130/0.4 at a dose of 7.5&#x000a0;ml/kg in the first hour of surgery, and then, Lactate Ringers&#x02019; was administrated 5&#x000a0;ml/kg until the end of the surgery. All data were presented as mean&#x02009;&#x000b1;&#x02009;SD or number of patients. <italic>ASA</italic> American Society of Anaesthesiologists, <italic>HES</italic> 6% hydroxyethyl starch 130/0.4, <italic>LR</italic> Lactate Ringers</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Patients&#x02019; comorbidities</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Comorbidities</th><th>HES(<italic>n</italic>&#x02009;=&#x02009;59)</th><th>LR(<italic>n</italic>&#x02009;=&#x02009;59)</th></tr></thead><tbody><tr><td>Hypertension,no.(%)</td><td>49(83.0)</td><td>51(86.4)</td></tr><tr><td>Diabetes mellitus(typeII),no.(%)</td><td>12(20.3)</td><td>10(16.9)</td></tr><tr><td>Stroke,no.(%)</td><td>1(1.7)</td><td>2(3.4)</td></tr><tr><td>COPD,no.(%)</td><td>1(1.7)</td><td>3(5.1)</td></tr><tr><td>CABG,no.(%)</td><td>2(3.4)</td><td>2(3.4)</td></tr></tbody></table><table-wrap-foot><p>
<italic>COPD</italic> chronic obstructive pulmonary disease, <italic>CABG</italic> coronary artery bypass graft, <italic>HES</italic> 6% hydroxyethyl starch 130/0.4, <italic>LR</italic> Lactate Ringers&#x02019;</p><p>Values are no. (%)</p></table-wrap-foot></table-wrap>
</p><p>A significant difference of MAP and HR between T<sub>0</sub> and T<sub>2-4</sub> was not observed in either of the groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). When compared with D<sub>0</sub>, the concentration of IL-18 in urine was dramatically enhanced in both the groups on D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>); however, no significant difference was seen between the two groups. Similarly, both groups showed a balanced plasma IL-18 at every time-point (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Intraoperative mean arterial blood pressure and heart rate</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Groups</th><th colspan="5">MAP(mmHg)</th><th colspan="5">HR(beats/min)</th></tr><tr><th>T<sub>0</sub>
</th><th>T<sub>1</sub>
</th><th>T<sub>2</sub>
</th><th>T<sub>3</sub>
</th><th>T<sub>4</sub>
</th><th>T<sub>0</sub>
</th><th>T<sub>1</sub>
</th><th>T<sub>2</sub>
</th><th>T<sub>3</sub>
</th><th>T<sub>4</sub>
</th></tr></thead><tbody><tr><td>HES</td><td>112&#x02009;&#x000b1;&#x02009;7</td><td>105&#x02009;&#x000b1;&#x02009;6</td><td>99&#x02009;&#x000b1;&#x02009;8</td><td char="&#x000b1;" align="char">100&#x02009;&#x000b1;&#x02009;6</td><td>101&#x02009;&#x000b1;&#x02009;7</td><td>65&#x02009;&#x000b1;&#x02009;3</td><td>68&#x02009;&#x000b1;&#x02009;5</td><td>66&#x02009;&#x000b1;&#x02009;4</td><td>67&#x02009;&#x000b1;&#x02009;5</td><td>63&#x02009;&#x000b1;&#x02009;4</td></tr><tr><td>LR</td><td>109&#x02009;&#x000b1;&#x02009;5</td><td>106&#x02009;&#x000b1;&#x02009;8</td><td>98&#x02009;&#x000b1;&#x02009;6</td><td char="&#x000b1;" align="char">96&#x02009;&#x000b1;&#x02009;7</td><td>99&#x02009;&#x000b1;&#x02009;6</td><td>70&#x02009;&#x000b1;&#x02009;2</td><td>69&#x02009;&#x000b1;&#x02009;3</td><td>71&#x02009;&#x000b1;&#x02009;5</td><td>66&#x02009;&#x000b1;&#x02009;6</td><td>65&#x02009;&#x000b1;&#x02009;3</td></tr></tbody></table><table-wrap-foot><p>Patients in group LR received intraoperative placebo Lactate Ringers&#x02019; at a dose of 7.5&#x000a0;ml/kg; Patients in group HES received 6% HES 130/0.4 at a dose of 7.5&#x000a0;ml/kg in the first hour of surgery, and then, Lactate Ringers&#x02019; was administrated 5&#x000a0;ml/kg until the end of the surgery. Haemodynamics data was evaluated and recorded at baseline (T<sub>0</sub>), before skin incision (T<sub>1</sub>), skin incision (T<sub>2</sub>), after skin incision (T<sub>3</sub>), surgery completed (T<sub>4</sub>). All data were presented as mean&#x02009;&#x000b1;&#x02009;SD. <italic>HES</italic> 6% hydroxyethyl starch 130/0.4, <italic>LR</italic> Lactate Ringers&#x02019;, <italic>MAP</italic> Mean arterial pressure</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Renal function</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>D<sub>0</sub>
</th><th>D<sub>1</sub>
</th><th>D<sub>2</sub>
</th><th>D<sub>3</sub>
</th><th>D<sub>4</sub>
</th></tr></thead><tbody><tr><td colspan="6">p-NGAL (ng/ml)</td></tr><tr><td>&#x02003;HES</td><td>4.0&#x02009;&#x000b1;&#x02009;0.3</td><td>4.2&#x02009;&#x000b1;&#x02009;0.5</td><td>4.3&#x02009;&#x000b1;&#x02009;0.5</td><td>4.2&#x02009;&#x000b1;&#x02009;0.5</td><td>4.4&#x02009;&#x000b1;&#x02009;0.6</td></tr><tr><td>&#x02003;LR</td><td>4.1&#x02009;&#x000b1;&#x02009;0.8</td><td>4.0&#x02009;&#x000b1;&#x02009;0.7</td><td>4.4&#x02009;&#x000b1;&#x02009;0.9</td><td>4.1&#x02009;&#x000b1;&#x02009;0.7</td><td>4.3&#x02009;&#x000b1;&#x02009;0.8</td></tr><tr><td colspan="6">u-NGAL (ng/ml)</td></tr><tr><td>&#x02003;HES</td><td>4.9&#x02009;&#x000b1;&#x02009;0.8</td><td>5.1&#x02009;&#x000b1;&#x02009;0.3</td><td>4.9&#x02009;&#x000b1;&#x02009;0.4</td><td>5.2&#x02009;&#x000b1;&#x02009;0.5</td><td>5.1&#x02009;&#x000b1;&#x02009;0.4</td></tr><tr><td>&#x02003;LR</td><td>5.6&#x02009;&#x000b1;&#x02009;0.7</td><td>5.2&#x02009;&#x000b1;&#x02009;0.4</td><td>4.9&#x02009;&#x000b1;&#x02009;0.3</td><td>5.0&#x02009;&#x000b1;&#x02009;0.3</td><td>5.1&#x02009;&#x000b1;&#x02009;0.3</td></tr><tr><td colspan="6">p-IL18 (&#x003bc;g/l)</td></tr><tr><td>&#x02003;HES</td><td>79.3&#x02009;&#x000b1;&#x02009;9.8</td><td>81.0&#x02009;&#x000b1;&#x02009;10.4</td><td>84.2&#x02009;&#x000b1;&#x02009;13.8</td><td>83.4&#x02009;&#x000b1;&#x02009;10.2</td><td>85.1&#x02009;&#x000b1;&#x02009;11.3</td></tr><tr><td>&#x02003;LR</td><td>81.0&#x02009;&#x000b1;&#x02009;14.5</td><td>81.4&#x02009;&#x000b1;&#x02009;9.0</td><td>83.8&#x02009;&#x000b1;&#x02009;12.5</td><td>86.5&#x02009;&#x000b1;&#x02009;14.1</td><td>81.5&#x02009;&#x000b1;&#x02009;6.1</td></tr><tr><td colspan="6">u-IL-18 (&#x003bc;g/l)</td></tr><tr><td>&#x02003;HES</td><td>82.7&#x02009;&#x000b1;&#x02009;8.5</td><td>89.5&#x02009;&#x000b1;&#x02009;5.8</td><td>109.6&#x02009;&#x000b1;&#x02009;9.2<sup>*</sup>
</td><td>140.5&#x02009;&#x000b1;&#x02009;10.9<sup>*</sup>
</td><td>159.7&#x02009;&#x000b1;&#x02009;16.9<sup>*</sup>
</td></tr><tr><td>&#x02003;LR</td><td>86.6&#x02009;&#x000b1;&#x02009;8.5</td><td>83.2&#x02009;&#x000b1;&#x02009;4.8</td><td>118.5&#x02009;&#x000b1;&#x02009;11.4<sup>*</sup>
</td><td>142.6&#x02009;&#x000b1;&#x02009;18.1<sup>*</sup>
</td><td>162.0&#x02009;&#x000b1;&#x02009;18.5<sup>*</sup>
</td></tr><tr><td colspan="6">eGFR (ml/min/1.73&#x000a0;m<sup>2</sup>)</td></tr><tr><td>&#x02003;HES</td><td>63.9&#x02009;&#x000b1;&#x02009;14.3</td><td>63.5&#x02009;&#x000b1;&#x02009;13.5</td><td>64&#x02009;&#x000b1;&#x02009;14.7</td><td>72.8&#x02009;&#x000b1;&#x02009;10.4</td><td>68.6&#x02009;&#x000b1;&#x02009;12.4</td></tr><tr><td>&#x02003;LR</td><td>61.9&#x02009;&#x000b1;&#x02009;8.3</td><td>63.5&#x02009;&#x000b1;&#x02009;9.6</td><td>63&#x02009;&#x000b1;&#x02009;6.2</td><td>64&#x02009;&#x000b1;&#x02009;9.4</td><td>66.4&#x02009;&#x000b1;&#x02009;9.2</td></tr><tr><td colspan="6">ACR</td></tr><tr><td>&#x02003;HES</td><td>1.96&#x02009;&#x000b1;&#x02009;0.21</td><td>1.98&#x02009;&#x000b1;&#x02009;0.19</td><td>1.90&#x02009;&#x000b1;&#x02009;0.09</td><td>1.99&#x02009;&#x000b1;&#x02009;0.13</td><td>1.95&#x02009;&#x000b1;&#x02009;0.20</td></tr><tr><td>&#x02003;LR</td><td>1.89&#x02009;&#x000b1;&#x02009;0.14</td><td>1.84&#x02009;&#x000b1;&#x02009;0.20</td><td>1.90&#x02009;&#x000b1;&#x02009;0.19</td><td>1.94&#x02009;&#x000b1;&#x02009;0.15</td><td>1.92&#x02009;&#x000b1;&#x02009;0.12</td></tr><tr><td colspan="6">u-&#x003b2;2 micro-albumin (mg/l)</td></tr><tr><td>&#x02003;HES</td><td>96.4&#x02009;&#x000b1;&#x02009;11.2</td><td>97.1&#x02009;&#x000b1;&#x02009;12.2</td><td>101.7&#x02009;&#x000b1;&#x02009;9.4</td><td>99.4&#x02009;&#x000b1;&#x02009;15.7</td><td>103.0&#x02009;&#x000b1;&#x02009;13.8</td></tr><tr><td>&#x02003;LR</td><td>93.2&#x02009;&#x000b1;&#x02009;8.9</td><td>90.6&#x02009;&#x000b1;&#x02009;8.2</td><td>99.8&#x02009;&#x000b1;&#x02009;14.2</td><td>104.7&#x02009;&#x000b1;&#x02009;15.0</td><td>93.2&#x02009;&#x000b1;&#x02009;12.3</td></tr><tr><td colspan="6">p-Creatinine (umol/l)</td></tr><tr><td>&#x02003;HES</td><td>92.5&#x02009;&#x000b1;&#x02009;9.3</td><td>94.6&#x02009;&#x000b1;&#x02009;7.9</td><td>93.1&#x02009;&#x000b1;&#x02009;9.1</td><td>81.2&#x02009;&#x000b1;&#x02009;8.6</td><td>85.9&#x02009;&#x000b1;&#x02009;7.7</td></tr><tr><td>&#x02003;LR</td><td>85.7&#x02009;&#x000b1;&#x02009;5.9</td><td>86&#x02009;&#x000b1;&#x02009;9.1</td><td>85.3&#x02009;&#x000b1;&#x02009;6.3</td><td>85.1&#x02009;&#x000b1;&#x02009;7.9</td><td>82.6&#x02009;&#x000b1;&#x02009;9.2</td></tr><tr><td colspan="6">u-Albumin (g/l)</td></tr><tr><td>&#x02003;HES</td><td>87.4&#x02009;&#x000b1;&#x02009;4.1</td><td>90.2&#x02009;&#x000b1;&#x02009;4.3</td><td>91.1&#x02009;&#x000b1;&#x02009;5.1</td><td>96.1&#x02009;&#x000b1;&#x02009;6.3</td><td>97.5&#x02009;&#x000b1;&#x02009;7.0</td></tr><tr><td>&#x02003;LR</td><td>86.6&#x02009;&#x000b1;&#x02009;5.7</td><td>87.1&#x02009;&#x000b1;&#x02009;2.8</td><td>92.3&#x02009;&#x000b1;&#x02009;3.8</td><td>97&#x02009;&#x000b1;&#x02009;4.7</td><td>98.1&#x02009;&#x000b1;&#x02009;6.4</td></tr></tbody></table><table-wrap-foot><p>Patients in group LR received intraoperative placebo Lactate Ringers&#x02019; at a dose of 7.5&#x000a0;ml/kg; Patients in group HES received 6% HES 130/0.4 at a dose of 7.5&#x000a0;ml/kg in the first hour of surgery, and then, Lactate Ringers&#x02019; was administrated 5&#x000a0;ml/kg until the end of the surgery. Blood and urine sample were got at five time points: before anaesthesia (D<sub>0</sub>), during surgery (D<sub>1</sub>), the first day after surgery (D<sub>2</sub>), the third day after surgery (D<sub>3</sub>), the fifth day after surgery (D<sub>4</sub>). ACR, eGFR, urine (u) and plasma (p) NGAL, plasma creatinine, urine &#x003b2;<sub>2</sub> micro-albumin and albumin were assessed. Values are presented as mean&#x02009;&#x000b1;&#x02009;SD, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. D<sub>0</sub>
</p><p>
<italic>HES</italic> 6% hydroxyethyl starch 130/0.4, <italic>LR</italic> Lactate Ringers&#x02019;, <italic>u</italic>-<italic>NGAL</italic> urine Neutrophil gelatinase&#x02013;associated lipocalin, <italic>p</italic>-<italic>NGAL</italic> plasma Neutrophil gelatinase&#x02013;associated lipocalin, <italic>eGFR</italic> estimated glomerular filtration rate, <italic>ACR</italic> ratio of urine trace albumin and urine creatinine</p></table-wrap-foot></table-wrap>
</p><p>A remarkable alteration in the levels of eGFR, ACR, urine and plasma NGAL, plasma creatinine, urine &#x003b2;<sub>2</sub> microalbumin, and trace albumin was not noted in both groups (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05, Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).</p></sec><sec id="Sec9"><title>Discussion</title><p>In the current study, we investigated the influence of intraoperative administration of lactate Ringer&#x02019;s and 6% HES 130/0.4 on elderly patients with normal renal function undergoing hip arthroplasty under spinal anesthesia. The objective of our study was to illustrate whether 6% HES 130/0.4 infusion played a nephrotoxic role that can be detected via blood pressure and concentrations of NGAL, IL18, &#x003b2;<sub>2</sub> microalbumin and albumin in urine and creatinine, as well as, NGAL and IL-18 in plasma. The elderly patients with normal renal function who underwent hip arthroplasty with spinal anesthesia demonstrated that intraoperative HES (500&#x000a0;mL) infusion did not cause postoperative AKI.</p><p>A recent study suggested that utilizing HES may elicit AKI in patients with sepsis. The current study selected elderly patients with normal renal function to accept spinal anesthesia and excluded the patients with infection, malignant tumors, and other factors that may affect the level of NGAL and IL-18 in plasma and urine. We discovered that urine IL-18 was increased significantly and similarly in both groups post-surgery, indicating that elderly patients are a high-risk population for the development of AKI. Furthermore, HES is not implicated in this process. The phenomenon in elderly patients of not developing AKI from the infusion of 6% HES 130/0.4 in our study might be attributed to the short duration of surgery and the small volume of HES infusion. A previous study suggested that AKI occurred after 36&#x000a0;h when septic patients received more than 2000&#x000a0;mL HES [<xref ref-type="bibr" rid="CR19">19</xref>]. The most dramatical difference between the recent multi-center studies (CRYSTMAS, 6S, and CHEST) and the current investigation is the patients&#x02019; characteristics. The CHEST study by Myburgh et al. included patients with signs of hypovolemia, the CRYSTMAS study by Guidet et al. and the 6S trial by Perner et al. included patients who suffered from clinically defined severe sepsis. Furthermore, the vast majority of the patients in these three studies were medical patients [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Contrastingly, the present study exclusively investigated elderly patients with normal kidney function. Thus, we considered that 500&#x000a0;mL HES would not contribute to AKI in elderly patients who required undergoing hip arthroplasty with spinal anesthesia.</p><p>IL-18 has been manifested as an indicator for the early prediction of AKI. Urinary IL-18 was considerably elevated for the diagnosis of AKI with sensitivity and specificity of 90%. To our knowledge, this is the first study to discover that urine IL-18 levels were significantly increased in elderly patients undergoing hip arthroplasty under the influence of spinal anesthesia. On the other hand, other indicators such as eGFR, ACR, plasma creatinine, blood and urine NGAL, and urine &#x003b2;<sub>2</sub> microglobulin levels did not show a remarkable alteration. According to the KDIGO AKI classification (the KDIGO 1 stage is a minimum increase in plasma creatinine concentration &#x0003e;50% or an increase in 27&#x000a0;&#x003bc;mol/L of creatinine within 48&#x000a0;h), all the patients in this study could not be diagnosed as AKI. However, we are convinced that the postoperative increase of urine IL-18 levels might be associated with mild renal tubular damage. Importantly, a significant difference in the urine level of IL-18 between the two groups was not observed, indicating that HES exposure is not the key reason of AKI in elderly patients.</p><p>Clinical studies have reported that NGAL production is a result of a marked immune response in the event of AKI. Simultaneously, NGAL is an independent predictor of AKI after sepsis, ischemia, or renal toxicity. Additionally, IL-18 has been identified as specific in ischemic AKI. We also found that IL-18 but not NGAL and other indicators experienced a rising trend, suggesting that the postoperative kidney damage may be due to the ischemic effect of spinal anesthesia. Thus, according to results, perioperative elderly patients are at high risk of ischemic AKI, and risk of ischemia should be avoided in such patients.</p><p>Although IL-18 was profoundly increased in both groups, it was not a sharp rise, suggesting that all the patients in the current study developed a mild renal inflammatory response potentially arising as a consequence of the surgery or anesthesia. This mild inflammatory response raised the level of IL-18 in urine, thereby increasing the load of glomerular filtration rate. Only when the concentration of plasma IL-18 attains a specific threshold, AKI would be generated [<xref ref-type="bibr" rid="CR26">26</xref>]. This may also explain why the patients in our study did not develop AKI, and the other indicators were not significantly increased, including NGAL.</p><p>One possible limitation of the present study is that only the end of the operation and 1, 3, and 5&#x000a0;days after operation were selected as the assessment time-points according to the time of AKI diagnosis. A further follow-up study on the minimal renal injury was lacking, and thus, we could not determine when the concentration of urine IL-18 decreased to baseline levels [<xref ref-type="bibr" rid="CR24">24</xref>]. In the future, additional clinical studies with a larger volume of HES and more time-points will be essential to substantiate the conclusion of the present study.</p></sec><sec id="Sec10"><title>Conclusion</title><p>In summary, the present data asserts that elderly patients with hip arthroplasty under spinal anesthesia are a high-risk population for AKI, and the risk of ischemia should be avoided. Furthermore, elderly patients with normal renal function receiving a spinal anesthesia for a short duration surgery would not develop AKI when a small amount of HES (500&#x000a0;mL) was infused. Yet, caution must be exercised in translating these results to an average clinical situation.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACR</term><def><p>Urine trace albumin/urine creatinine ratio</p></def></def-item><def-item><term>AKI</term><def><p>Acute kidney injury</p></def></def-item><def-item><term>eGFR</term><def><p>Estimated glomerular filtration rate</p></def></def-item><def-item><term>HES</term><def><p>Hydroxyethyl starch 130/0.4</p></def></def-item><def-item><term>LR</term><def><p>Lactate Ringer&#x02019;s</p></def></def-item><def-item><term>NGAL</term><def><p>Neutrophil gelatinase-associated lipocalin</p></def></def-item></def-list></glossary><ack><p>Not applicable.</p><sec id="FPar1"><title>Funding</title><p>This study was supported by the research grants from the National Natural Science Foundation of China (81471842). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets analyzed and/or during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>YZ &#x00026; YY conceived the experiment; WY &#x00026; RX &#x00026; LG &#x00026; YW collected the data; JJ analyzed the data; YZ &#x00026; YY wrote the paper. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The study protocol was approved by the Ethics Committee of Tianjin Medical University General Hospital (Tianjin, China, Approval Number: IRB2014-102-01), and the trial registration is <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</ext-link>; identifier: <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT02361736">NCT02361736</ext-link>. Each participant provided written informed consent. This randomized, double-blind, controlled, multi-center study was performed in the operating rooms in Tianjin Medical University General Hospital, Tianjin Union Medical Center, and Tianjin First Central Hospital from February 2015 to January 2016.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldheiser</surname><given-names>A</given-names></name><name><surname>Pavlova</surname><given-names>V</given-names></name><name><surname>Bonomo</surname><given-names>T</given-names></name></person-group><article-title>Balanced crystallid compared with balanced colloidsolution using a goal-directed haemodynamicalgorithm</article-title><source>Br J Anaesth</source><year>2013</year><volume>110</volume><fpage>231</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/bja/aes377</pub-id><pub-id pub-id-type="pmid">23112214</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIlroy</surname><given-names>DR</given-names></name><name><surname>Kharasch</surname><given-names>ED</given-names></name></person-group><article-title>Acute intravascular volume expansion with rapidly administered or colloid in the setting of moderate hypovolemia</article-title><source>AnesthAnalg</source><year>2003</year><volume>96</volume><fpage>1572</fpage><lpage>7</lpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x02019;Hermite</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>L</given-names></name><name><surname>Cuvillon</surname><given-names>P</given-names></name></person-group><article-title>Stroke volume optimization after anaestheticinduction: An open randomized controlled trial comparing 0.9%NaCl versus 6% hydroxylethyl starch 130/0.4</article-title><source>Ann FrAnesthReanim</source><year>2013</year><volume>32</volume><fpage>e121</fpage><lpage>7</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>Z</given-names></name><name><surname>Cruz</surname><given-names>D</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name></person-group><article-title>The RIFLE criteria and mortality in acute kidney injury: A systematic review</article-title><source>Kidney Int</source><year>2008</year><volume>73</volume><fpage>538</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5002743</pub-id><pub-id pub-id-type="pmid">18160961</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>M</given-names></name><name><surname>Story</surname><given-names>DA</given-names></name><name><surname>Haase-Fielitz</surname><given-names>A</given-names></name></person-group><article-title>Renal injury in the elderly: Diagnosis, biomarkers and prevention</article-title><source>Best Pract Res ClinAnaesthesiol</source><year>2011</year><volume>25</volume><fpage>401</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2011.06.004</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagener</surname><given-names>G</given-names></name><name><surname>Jan</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name></person-group><article-title>Association between increases in urinary neutrophilgelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery</article-title><source>Anesthesiology</source><year>2006</year><volume>105</volume><fpage>485</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1097/00000542-200609000-00011</pub-id><pub-id pub-id-type="pmid">16931980</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>E</given-names></name><name><surname>Mark&#x000f3;</surname><given-names>L</given-names></name><name><surname>Paragas</surname><given-names>N</given-names></name><name><surname>Barasch</surname><given-names>J</given-names></name><name><surname>Dragun</surname><given-names>D</given-names></name></person-group><article-title>Neutrophil gelatinase-associated lipocalin: Pathophysiology and clinical applications</article-title><source>ActaPhysiol (Oxf)</source><year>2013</year><volume>207</volume><fpage>663</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/apha.12054</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schinstock</surname><given-names>CA</given-names></name><name><surname>Semret</surname><given-names>MH</given-names></name><name><surname>Wagner</surname><given-names>SJ</given-names></name></person-group><article-title>Urinalysis is more specific and urinary neutrophilgelatinse-associated lipocalin is more sensitive for early detection of acute kidney injury</article-title><source>Nephrol Dial Transplant</source><year>2013</year><volume>28</volume><fpage>1175</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfs127</pub-id><pub-id pub-id-type="pmid">22529161</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>CR</given-names></name><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Thiessen-Philbrook</surname><given-names>H</given-names></name><etal/></person-group><article-title>Urinary IL-18 is an early predictivebiomarker of acute kidney injury after cardiac surgery [J]</article-title><source>Kidney Int</source><year>2006</year><volume>70</volume><issue>1</issue><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1038/sj.ki.5001527</pub-id><pub-id pub-id-type="pmid">16710348</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>CR</given-names></name><name><surname>Jani</surname><given-names>A</given-names></name><name><surname>Melmikov</surname><given-names>VY</given-names></name></person-group><article-title>Urinary interleukin-18 is a marker of human acute tubular necrosis</article-title><source>Am J Kidney Dis</source><year>2004</year><volume>42</volume><issue>3</issue><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2003.10.040</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>CR</given-names></name><name><surname>Abraham</surname><given-names>E</given-names></name><name><surname>Ancukiewicz</surname><given-names>M</given-names></name></person-group><article-title>Urine IL-18 is an early diagnostic marker foracute kidney injury and predicts mortality in the intensive care unit</article-title><source>J Am SocNephrol</source><year>2005</year><volume>16</volume><issue>10</issue><fpage>3046</fpage><lpage>52</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellmann</surname><given-names>R</given-names></name><name><surname>Feistritzer</surname><given-names>C</given-names></name><name><surname>Wiedermann</surname><given-names>CJ</given-names></name></person-group><article-title>Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: A meta-analysis of clinical studies</article-title><source>ClinPharmacokinet</source><year>2012</year><volume>51</volume><fpage>225</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.2165/11594700-000000000-00000</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perazella</surname><given-names>MA</given-names></name></person-group><article-title>Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity</article-title><source>Am J Med Sci</source><year>2003</year><volume>325</volume><fpage>349</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1097/00000441-200306000-00006</pub-id><pub-id pub-id-type="pmid">12811231</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cittanova</surname><given-names>ML</given-names></name><name><surname>Leblanc</surname><given-names>I</given-names></name><name><surname>Legendre</surname><given-names>C</given-names></name></person-group><article-title>Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients</article-title><source>Lancet</source><year>1996</year><volume>348</volume><fpage>1620</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(96)07588-5</pub-id><pub-id pub-id-type="pmid">8961992</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickenmann</surname><given-names>M</given-names></name><name><surname>Oettl</surname><given-names>T</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name></person-group><article-title>Osmotic nephrosis: Acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes</article-title><source>Am J Kidney Dis</source><year>2008</year><volume>51</volume><fpage>491</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2007.10.044</pub-id><pub-id pub-id-type="pmid">18295066</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azevedo</surname><given-names>VL</given-names></name><name><surname>Santos</surname><given-names>PS</given-names></name><name><surname>Oliveira</surname><given-names>GS</given-names><suffix>Jr</suffix></name></person-group><article-title>The effect of 6% hydroxyethyl starch vs. Ringer&#x02019;s lactate on acute kidney injury after renal ischemia in rats</article-title><source>Acta Cir Bras</source><year>2013</year><volume>28</volume><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1590/S0102-86502013000100002</pub-id><pub-id pub-id-type="pmid">23338107</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schick</surname><given-names>MA</given-names></name><name><surname>Isbary</surname><given-names>TJ</given-names></name><name><surname>Schlegel</surname><given-names>N</given-names></name></person-group><article-title>The impact of crystalloid and colloid infusion on the kidney in rodent sepsis</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><fpage>541</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1704-0</pub-id><pub-id pub-id-type="pmid">19890625</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perner</surname><given-names>A</given-names></name><name><surname>Haase</surname><given-names>N</given-names></name><name><surname>Guttormsen</surname><given-names>AB</given-names></name><collab>6S Trail Group</collab><collab>Scandinavian Critical Care Trials Group</collab></person-group><article-title>Hydroxyethyl starch 130/0.42 versus Ringer&#x02019;s acetate in severe sepsis</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>124</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1204242</pub-id><pub-id pub-id-type="pmid">22738085</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidet</surname><given-names>B</given-names></name><name><surname>Martinet</surname><given-names>O</given-names></name><name><surname>Boulain</surname><given-names>T</given-names></name></person-group><article-title>Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study</article-title><source>Crit Care</source><year>2012</year><volume>16</volume><fpage>R94</fpage><pub-id pub-id-type="doi">10.1186/cc11358</pub-id><pub-id pub-id-type="pmid">22624531</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamaji</surname><given-names>A</given-names></name><name><surname>Hajjar</surname><given-names>L</given-names></name><name><surname>Caiero</surname><given-names>M</given-names></name></person-group><article-title>Volum replacement therapy during hip arthroplasty using hydroxyethyl starch (130/0.4) compared to lactated Ringer decreases allogeneic blood transfusion and postoperative infection</article-title><source>Braz J Anesthesiol</source><year>2013</year><volume>63</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/S0034-7094(13)70196-X</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenger-Eriksen</surname><given-names>C</given-names></name><name><surname>Hartig Rasmussen</surname><given-names>C</given-names></name><name><surname>Kappel Jensen</surname><given-names>T</given-names></name></person-group><article-title>Renal effects of hypotensive anaesthesia in combination with acute normovolaemichaemodilution with hydroxyethyl starch 130/0.4 or isotonic saline</article-title><source>Acta AnaesthesiolScand</source><year>2005</year><volume>49</volume><fpage>969</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2005.00714.x</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Der Linden</surname><given-names>P</given-names></name><name><surname>James</surname><given-names>M</given-names></name><name><surname>Mythen</surname><given-names>M</given-names></name><name><surname>Weiskopf</surname><given-names>RB</given-names></name></person-group><article-title>Safety of modern starches used during surgery</article-title><source>Anesth Analg</source><year>2013</year><volume>116</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1213/ANE.0b013e31827175da</pub-id><pub-id pub-id-type="pmid">23115254</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Vicaut</surname><given-names>E</given-names></name></person-group><article-title>Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients</article-title><source>Anesthesiology</source><year>2013</year><volume>118</volume><fpage>387</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e31827e5569</pub-id><pub-id pub-id-type="pmid">23340352</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>CR</given-names></name><name><surname>Jani</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>J</given-names></name></person-group><article-title>Urine NGAL and IL-18 are predictivebiomarkers for dilayed graft functionfollowing kidney transplantation</article-title><source>Am J Transplant</source><year>2006</year><volume>6</volume><issue>7</issue><fpage>1639</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2006.01352.x</pub-id><pub-id pub-id-type="pmid">16827865</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myburgh</surname><given-names>JA</given-names></name><name><surname>Finfer</surname><given-names>S</given-names></name><name><surname>Bellomo</surname><given-names>R</given-names></name></person-group><article-title>Hydroxyethyl starch or saline for fluid resuscitation in intensive care</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><issue>20</issue><fpage>1901</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209759</pub-id><pub-id pub-id-type="pmid">23075127</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>C</given-names></name><name><surname>Fuke</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Serum interleukin-18 binding protein increases with behavior different from IL-18 in patients with diabetic nephropathy</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>92</volume><fpage>e66</fpage><lpage>e69</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2011.02.028</pub-id><pub-id pub-id-type="pmid">21440322</pub-id></element-citation></ref></ref-list></back></article>